$2.98
-0.03 (-1.00%)
Open$3.04
Previous Close$3.01
Day High$3.08
Day Low$2.87
52W High$5.38
52W Low$2.01
Volume—
Avg Volume375.9K
Market Cap116.02M
P/E Ratio—
EPS$-3.50
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+604.7% upside
Current
$2.98
$2.98
Target
$21.00
$21.00
$13.91
$21.00 avg
$28.26
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.03M | 5.08M | 4.69M |
| Net Income | 1.10M | 914.1K | 814.2K |
| Profit Margin | 21.9% | 18.0% | 17.4% |
| EBITDA | 1.45M | 1.42M | 1.49M |
| Free Cash Flow | 1.19M | 761.6K | 738.1K |
| Rev Growth | -9.3% | +7.5% | +3.9% |
| Debt/Equity | 1.05 | 1.23 | 1.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |